5 Reasons Why Your Business Needs citicoline poeder？

Adibhatla, R. M., Hatcher JF, and Dempsey RJ. Effects of citicholine on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 2001;32(10):2376-2381.

If you are looking for more details, kindly visit citicoline poeder.

Agnoli A, Fioravanti M, and Lechner H. Efficacy of CDP-Choline in chronic cerebral vascular diseases (CCVD). In: Zappia V, Kennedy EP, Nilsson BI, and Galletti PV. Novel Biochemical, Pharmacological, and Clinical Aspects of Cytidinediphosphocholine. New York: Elsevier Science;1985.

Aizawa, K., Kanai, T., Saikawa, Y., Takabayashi, T., Kawano, Y., Miyazawa, N., and Yamamoto, T. A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery. Surg.Today. 2002;32(4):310-314. View abstract.

Alvarez, X. A., Laredo, M., Corzo, D., Fernandez-Novoa, L., Mouzo, R., Perea, J. E., Daniele, D., and Cacabelos, R. Citicoline improves memory performance in elderly subjects. Methods.Find.Exp.Clin.Pharmacol. 1997;19(3):201-210. View abstract.

Alvarez, X. A., Mouzo, R., Pichel, V., Perez, P., Laredo, M., Fernandez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J. J., Lozano, R., and Cacabelos, R. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods.Find.Exp.Clin.Pharmacol. 1999;21(9):633-644. View abstract.

Angeli G. Clinical study on Asonic (provisional name) [Sperimentazione clinica sul prodotto denominato provvisoriamente Asonic]. Rivista di Neuropsichiatria e Scienze Affini 1985;31:13-24.

Arranz, J. and Ganoza, C. Treatment of chronic dyskinesia with CDP-choline. Arzneimittelforschung. 1983;33(7A):1071-1073. View abstract.

Ataus S, Onal M, Zulkuf M, and et al. The effects of citicholine and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats. International Journal of Neuroscience 2004;114(2):183-196.

Babb, S. M., Wald, L. L., Cohen, B. M., Villafuerte, R. A., Gruber, S. A., Yurgelun-Todd, D. A., and Renshaw, P. F. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology.(Berl.) 2002;161(3):248-254. View abstract.

Barbagallo-Sangiorgi G, Ceruso D, Cuzzupoli MF, and et al. Double-blind, multicenter study on CDP-choline in patients with primary senile mental deterioration [Studio multicentrico in doppio cieco con Citicolina nel deterioramento mentale senile primitivo]. Invecchiamento Cerebrale e Cerebrovasculopatie Croniche 1988;

Berggren, D., Gustafson, Y., Eriksson, B., Bucht, G., Hansson, L. I., Reiz, S., and Winblad, B. Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth.Analg. 1987;66(6):497-504. View abstract.

Bettini, R. and Gorini, M. [Reaction times during citicoline treatment]. Clin.Ter. 2002;153(4):247-250. View abstract.

Bonavita E, Chioma V, Dall'Oca P, and et al. Double-blind study on CDP-choline activity in primitive mild cognitive deterioration cases [Studio in doppio cieco sull'azione della citicolina nel cervello senile]. Minerva Psichiatrica 1983;24:53-62.

Bonavita, E. [Neuropsychological study of the senile brain during and after single and combined treatment with deanol and citicoline]. Clin.Ter. 6-15-1986;117(5):387-398. View abstract.

Brown, E. S., Gorman, A. R., and Hynan, L. S. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin.Psychopharmacol. 2007;27(5):498-502. View abstract.

Campos, E. C., Schiavi, C., Benedetti, P., Bolzani, R., and Porciatti, V. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes.Arch Clin.Exp.Ophthalmol. 1995;233(5):307-312. View abstract.

Capurso A, Capurso S, Panza F, and et al. Efficacy of cytidine diphosphate choline in patients affected by chronic cerebrovascular disease. Clinical Drug Investigation 1996;12(1):26-38.

Centrone, G., Ragno, G., and Calicchio, G. [Use of citicoline in high dosages in acute cerebrovascular disease]. Minerva Med 3-17-1986;77(11):371-373. View abstract.

Clark, W. M., Warach, S. J., Pettigrew, L. C., Gammans, R. E., and Sabounjian, L. A. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology. 1997;49(3):671-678. View abstract.

Clark, W. M., Wechsler, L. R., Sabounjian, L. A., and Schwiderski, U. E. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 11-13-2001;57(9):1595-1602. View abstract.

Clark, W. M., Williams, B. J., Selzer, K. A., Zweifler, R. M., Sabounjian, L. A., and Gammans, R. E. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999;30(12):2592-2597. View abstract.

Cubells, J. M. and Hernando, C. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease. Clin.Ther 1988;10(6):664-671. View abstract.

D'Orlando, K. J. and Sandage, B. W., Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol.Res 1995;17(4):281-284. View abstract.

Di, Trapani G. and Fioravanti, M. [Citicoline in the treatment of cognitive and behavioral disorders in pathologic senile decline]. Clin.Ter. 6-30-1991;137(6):403-413. View abstract.

Diaz, V., Rodriguez, J., Barrientos, P., Serra, M., Salinas, H., Toledo, C., Kunze, S., Varas, V., Santelices, E., Cabrera, C., Farias, J., Gallardo, J., Beddings, M. I., Leiva, A., and Cumsille, M. A. [Use of procholinergics in the prevention of postoperative delirium in hip fracture surgery in the elderly. A randomized controlled trial]. Rev.Neurol. 10-16-2001;33(8):716-719. View abstract.

Dinsdale, J. R., Griffiths, G. K., Castello, J., Maddock, J., Ortiz, J. A., and Aylward, M. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittelforschung. 1983;33(7A):1061-1065. View abstract.

Dinsdale, J. R., Griffiths, G. K., Rowlands, C., Castello, J., Ortiz, J. A., Maddock, J., and Aylward, M. Pharmacokinetics of 14C CDP-choline. Arzneimittelforschung. 1983;33(7A):1066-1070. View abstract.

Eberhardt, R., Birbamer, G., Gerstenbrand, F., Rainer, E., and Traegner, H. Citicoline in the treatment of Parkinson's disease. Clin.Ther 1990;12(6):489-495. View abstract.

Falchi Delitata G, Falchi Delitata N, Casali R, and et al. Intermediate term, double-blind vs. placebo study of CDP-choline in cases with cognitive senile deterioration. Gazzetta Medica Italiana - Archivio Scienze Mediche 1984;143:789-810.

Fioravanti, M. and Yanagi, M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database.Syst.Rev. 2004;(2):CD000269. View abstract.

Fridman, E. A., Ottaviano, F., Fiol, M., Javelier, A., Perea, J. E., and Ameriso, S. F. [Neuroprotection in acute ischemic stroke. Practicability of guidelines for treatment]. Rev.Neurol. 5-1-2001;32(9):818-821. View abstract.

Iranmanesh, F. and Vakilian, A. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. J Stroke.Cerebrovasc.Dis. 2008;17(3):153-155. View abstract.

Kalisvaart, K. J., de Jonghe, J. F., Bogaards, M. J., Vreeswijk, R., Egberts, T. C., Burger, B. J., Eikelenboom, P., and van Gool, W. A. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am.Geriatr Soc 2005;53(10):1658-1666. View abstract.

León-Carrión J, Dominguez-Roldán JM, Murillo-Cabezas F, Dominguez-Morales MR, and Munoz-Sanchez MA. The role of citicholine in neuropsychological training after traumatic brain injury. NeuroRehabilitation 2000;14(1):33-40.

Liptzin B, Laki A, Garb, and et al. Donepezil in the Prevention and Treatment of Post-Surgical Delirium. American Journal of Geriatric Psychiatry 2005;13:1100-1106.

Lozano, Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung. 1983;33(7A):1073-1080. View abstract.

Lukas, S. E., Kouri, E. M., Rhee, C., Madrid, A., and Renshaw, P. F. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology.(Berl.) 2001;157(2):163-167. View abstract.

Madariaga Aguirre L. A double-blind evaluation on a group of senile female patients, treated with CDP-choline. Revista de Psiquiatría y Psicología Médica 1978;13(5):331-342.

Marcantonio, E. R., Flacker, J. M., Wright, R. J., and Resnick, N. M. Reducing delirium after hip fracture: a randomized trial. J Am.Geriatr Soc 2001;49(5):516-522. View abstract.

Marti Masso, J. F. and Urtasun, M. Citicoline in the treatment of Parkinson's disease. Clin.Ther 1991;13(2):239-242. View abstract.

Motta L, Fichera G, Tiralosi G, and et al. CDP-choline in the treatment of chronic cerebrovasculopaties [La citicolina nel tratta mento delle cerebrovasculopatie croniche]. Unpublished Lederle (Cyanamid Italia) report. 1985;

Parisi, V., Coppola, G., Centofanti, M., Oddone, F., Angrisani, A. M., Ziccardi, L., Ricci, B., Quaranta, L., and Manni, G. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog.Brain.Res 2008;173:541-554. View abstract.

Parisi, V., Coppola, G., Ziccardi, L., Gallinaro, G., and Falsini, B. Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur.J Neurol. 2008;15(5):465-474. View abstract.

Parisi, V., Manni, G., Colacino, G., and Bucci, M. G. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106(6):1126-1134. View abstract.

Pecori, Giraldi J., Virno, M., Covelli, G., Grechi, G., and De, Gregorio F. Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol. 1989;13(1-2):109-112. View abstract.

Petkov, V. D., Stancheva, S. L., Tocuschieva, L., and Petkov, V. V. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen.Pharmacol. 1990;21(1):71-75. View abstract.

Piccoli, F., Battistini, N., Carbonin, P., Curro, Dossi B., Fiori, L., La, Bella, V, Megna, G., Salvioli, G., and Fioravanti, M. CDP-choline in the treatment of chronic cerebrovasculopathies. Arch Gerontol Geriatr 1994;18(3):161-168. View abstract.

Radad K, Gille G, Xiaojing J, Durany N, and Rausch W-D. CDP-choline reduces dopaminergic cell loss induced by MPP-super(+) and glutamate in primary mesencephalic cell culture. International Journal of Neuroscience 2007;117(7):985-998.

Renshaw, P. F., Daniels, S., Lundahl, L. H., Rogers, V., and Lukas, S. E. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology.(Berl.) 1999;142(2):132-138. View abstract.

Rossi, M. and Zanardi, M. [An open study on the clinical efficacy of citicoline in patients with chronic cerebral vasculopathy]. Clin.Ter. 1993;142(2):141-144. View abstract.

Salvadorini F. Clinical evaluation of CDP-choline (Nicholin): Efficacy as antidepressant treatment. Therapeutic Research 1975;18(3):513-520.

Secades, J. J. and Lorenzo, J. L. Citicoline: pharmacological and clinical review, 2006 update. Methods.Find.Exp.Clin.Pharmacol. 2006;28 Suppl B:1-56. View abstract.

Secades, J. J., Alvarez-Sabin, J., Rubio, F., Lozano, R., Davalos, A., and Castillo, J. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc.Dis. 2006;21(5-6):380-385. View abstract.

Senin U and Fioravanti M. Clinical controlled study vs placebo of CDPcholine in a large group of aged patients with cerebrovascular dementia. Wyeth, Italy 2003;

Serra, F., Diaspri, G. P., Gasbarrini, A., Giancane, S., Rimondi, A., Tame, M. R., Sakellaridis, E., Bernardi, M., and Gasbarrini, G. [Effect of CDP-choline on senile mental deterioration. Multicenter experience on 237 cases]. Minerva Med. 1990;81(6):465-470. View abstract.

Siddiqi, N., Stockdale, R., Britton, A. M., and Holmes, J. Interventions for preventing delirium in hospitalised patients. Cochrane Database.Syst.Rev. 2007;(2):CD005563. View abstract.

Sinforiani E, Trucco M, Pacchetti C, and et al. Assessment of CDPcholine effects in patients with chronic cerebrovascular disease [Valutazione degli effetti della citicolina nella malattia cerebro-vascolare cronica]. Minerva Medica 1986;77(51):57.

Sinforiani, E., Trucco, M., Pacchetti, C., and Gualtieri, S. [Evaluation of the effects of citicoline in chronic cerebrovascular diseases]. Minerva Med 1-14-1986;77(1-2):51-57. View abstract.

Stramba-Badiale, M. and Scillieri, E. [Citicoline activity in senile mental decay]. Minerva Med 4-7-1983;74(14-15):819-821. View abstract.

Suryani L, Adnjana T, and Jensen G. Citicholine treatment of memory deficits in elderly people. International Journal of Geriatric Psychiatry 1988;3(3):235-236.

Tanaka, Y., Minematsu, K., Hirano, T., Hayashida, K., and Yamaguchi, T. [Effects of CDP-choline on dynamic changes in LCBF and cognitive function in demented subjects--an H2 15O-PET study]. Rinsho.Shinkeigaku. 1994;34(9):877-881. View abstract.

Trovarelli, G., de Medio, G. E., Dorman, R. V., Piccinin, G. L., Horrocks, L. A., and Porcellati, G. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil. Neurochem.Res 1981;6(8):821-833. View abstract.

Virno, M., Pecori-Giraldi, J., Liguori, A., and De, Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol.Scand.Suppl 2000;(232):56-57. View abstract.

Warach, S., Pettigrew, L. C., Dashe, J. F., Pullicino, P., Lefkowitz, D. M., Sabounjian, L., Harnett, K., Schwiderski, U., and Gammans, R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann.Neurol. 2000;48(5):713-722. View abstract.

Xiong, Y., Liu, X., Wang, Y., and Du, Y. Cloning of cytidine triphosphate: phosphocholine cytidylyltransferase mRNA upregulated by a neuropeptide arginine-vasopressin((4-8)) in rat hippocampus. Neurosci.Lett. 4-7-2000;283(2):129-132. View abstract.

Yashima, K., Takamatsu, M., and Okuda, K. Intestinal absorption of cytidine diphosphate choline and its changes in the digestive tract. J Nutr Sci Vitaminol.(Tokyo) 1975;21(1):49-60. View abstract.

Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res 2003;73:308-15. View abstract.

Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002;70:133-9. View abstract.

Aidelbaum R, Labelle A, Baddeley A, Knott V. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: a pilot study. J Psychopharmacol. 2018;32(5):541-51. View abstract.

Babb SM, Appelmans KE, Renshaw PF, et al. Differently effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by magnetic resonance spectroscopy. Psychopharmacology (Berl) 1996;127:88-94. View abstract.

Barrachina M, Dominguez I, Ambrosio S, et al. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. J Neurol Sci 2003;215:105-10. View abstract.

Brown ES, Todd JP, Hu LT, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry 2015;172(10):1014-21. View abstract.

Castagna A, Manzo C, Fabbo A, Lacava R, Ruberto C, Ruotolo G. The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease. Clin Drug Investig. 2021 Feb;41(2):177-182. View abstract.

Cinar E, Yuce B, Aslan F, Erbakan G. Neuroprotective effect of citicoline eye drops on corneal sensitivity after LASIK. J Refract Surg. 2019 Dec 1;35(12):764-770. View abstract.

Clark BC, Georgekutty J, Berul CI. Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients. J Pediatr 2015;167(3):757-61.e1. View abstract.

Cohen RA, Browndyke JN, Moser DJ, et al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: Neuroimaging and neuropsychological outcomes. Cerebrovasc Dis 2003;16:199-204. View abstract.

Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive function in the elderly: A review of the literature. Altern Med Rev 2004;9:17-31. View abstract.

Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging 2013;8:131-7. View abstract.

Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012;380(9839):349-57. View abstract.

Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: An individual patient date pooling analysis of clinical trials. Stroke 2002;33:2850-7. View abstract.

Dempsey RJ, Raghavendra Rao VL. Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. J Neurosurg 2003;98:867-73. View abstract.

El Sayed I, Zaki A, Fayed AM, Shehata GM, Abdelmonem S. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev 2018;41(2):427-38. View abstract.

Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005;(2):CD000269. View abstract.

Fogagnolo P, Melardi E, Tranchina L, Rossetti L. Topical citicoline and vitamin B12 versus placebo in the treatment of diabetes-related corneal nerve damage: a randomized double-blind controlled trial. BMC Ophthalmol. 2020 Aug 1;20(1):315.View abstract.

Ghajar A, Gholamian F, Tabatabei-Motlagh M, et al. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Hum Psychopharmacol. 2018;33(4):e2662. View abstract.

Jeong H, Yoon S, Sung YH, et al. Effects of cytidine-5'-diphosphate choline on gray matter volumes in methamphetamine-dependent patients: A randomized, double-blind, placebo-controlled study. J Psychiatr Res 2021;143:215-221. View abstract.

Licata SC, Penetar DM, Ravichandran C, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addict Med 2011;5(1):57-64. View abstract.

Loebis R, Zulkarnain BS, Siswanto FA. Effectiveness of citicoline in pediatric patients with refractive amblyopia in Surabaya, East Java, Indonesia. J Basic Clin Physiol Pharmacol 2021;32(4):657-661. View abstract.

Marino PF, Rossi GCM, Campagna G, et al. Effects of citicoline, homotaurine, and vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: A preliminary study. Molecules. 2020 Nov 29;25(23):5614. View abstract.

Martí-Carvajal AJ, Valli C, Martí-Amarista CE, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev. 2020 Aug 29;8:CD013066. View abstract.

Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr 2021;151(8):2153-2160. View abstract.

Ottobelli L, Manni GL, Centofanti M, et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica 2013;229(4):219-26. View abstract.

Parisi V, Centofanti M, Ziccardi L, et al. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2015;253(8):1327-40. View abstract.

Parravano M, Scarinci F, Parisi V, et al. Citicoline and vitamin B12 eye drops in type 1 diabetes: Results of a 3-year pilot study evaluating morpho-functional retinal changes. Adv Ther. 2020 Apr;37(4):1646-1663. View abstract.

Pawar PV, Mumbare SS, Patil MS, Ramakrishnan S. Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial. Indian J Ophthalmol 2014;62(2):124-9. View abstract.

Rejdak R, Toczolowski J, Krukowski J, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 2003;9:PI24-8. View abstract.

Roohi-Azizi M, Arabzadeh S, Amidfar M, et al. Citicoline combination therapy for major depressive disorder: a randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2017;40(1):1-5. View abstract.

Rossetti L, Iester M, Tranchina L, et al. Can treatment with citicoline eyedrops reduce progression in glaucoma? The results of a randomized placebo-controlled clinical trial. J Glaucoma. 2020 Jul;29(7):513-520. View abstract.

Salamah A, Mehrez M, Faheem A, El Amrousy D. Efficacy of Citicoline as a Neuroprotector in children with post cardiac arrest: a randomized controlled clinical trial. Eur J Pediatr. 2021 Apr;180(4):1249-1255. View abstract.

Savci V, Goktalay G, Cansev M, et al. Intravenously injected citicoline increases blood pressure and reverses hypotension in haemorrhagic shock: effect is mediated by central cholinergic activation. Eur J Pharmacol 2003;468:129-39. View abstract.

Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis 2016;25(8):1984-96. View abstract.

Shi PY, Zhou XC, Yin XX, Xu LL, Zhang XM, Bai HY. Early application of citicoline in the treatment of acute stroke: a meta-analysis of randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci 2016;36(2):270-7. View abstract.

Sobrado M, Lopez MG, Carceller F, et al. Combined nipodimine and citicoline reduce infarct size, attenuate apoptosis, and increase BCL-2 expression after focal cerebral ischemia. Neuroscience 2003;118:107-13. View abstract.

Spiers PA, Myers D, Hochanadel GS, et al. Citicoline improves verbal memory in aging. Arch Neurol 1996;53:441-8. View abstract.

Teather LA, Wurtman RJ. Dietary cytidine (5)-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:711–17. View abstract.

Trimmel H, Majdan M, Wodak A, Herzer G, Csomor D, Brazinova A. Citicoline in severe traumatic brain injury: indications for improved outcome: a retrospective matched pair analysis from 14 Austrian trauma centers. Wien Klin Wochenschr. 2018;130(1-2):37-44. View abstract.

Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995;56:637-60. View abstract.

Zemel MB, Thompson W, Milstead A, et al. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res 2004;12:582–90. View abstract.

Zweifler RM. Membrane stabilizer: Citicoline. Curr Med Res Opin 2002;18:s14-s17. View abstract.

Citicoline, also known as cytidine-5’-diphosphocholine or CDP-choline, is a fat molecule that is an important part of the cell membrane.

Researchers have studied citicoline in the setting of neurological (brain and nerve) diseases, such as dementia. It is commonly used to enhance cognitive function.

This article discusses citicoline's potential benefits and safety.

Citicoline Supplement Facts

• Active Ingredient(s): Citicoline
• Alternate Name(s): Cytidine-5’-diphosphocholine (CDP-choline)

• Legal Status: Over-the-counter (OTC) dietary supplement (United States); prescription drug (Japan and Europe)

• Suggested Dose: The therapeutic dose of citicoline ranges from 500 to 2,000 milligrams (mg) per day.
  Citicoline can be given intravenously (IV, within a vein), intramuscularly (within a muscle), and orally (by mouth).
• Safety Considerations: Caution should be taken if you are pregnant or breastfeeding because the safety of citicoline is unknown in these populations.

What Is Citicoline?

Citicoline has been studied to treat the following conditions:

• Brain stroke
• Dementia prevention and treatment
• Traumatic brain injury
• Nerve pain and injury (animal models)

Citicoline has improved cognition in people with neurological conditions. And it has also improved memory and cognitive function in healthy people.

The company is the world’s best Best Quality Citicoline Sodium supplier. We are your one-stop shop for all needs. Our staff are highly-specialized and will help you find the product you need.

Citicoline works to protect the brain by:

• Increasing dopamine,

  norepinephrine

  , and serotonin levels
• Serving as a precursor to

  acetylcholine

  , a type of chemical messenger that helps brain and body functions
• Lowering levels of

  glutamate

  , a brain chemical that causes damage to the brain under low oxygen conditions
• Blocking

  phospholipase

  A2, a type of enzyme that then reduces inflammation
  

Older adult solving a crossword puzzle.

Goodboy Picture Company / Getty Images

Uses

Supplement use should be individualized and vetted by a healthcare professional, such as a registered dietitian (RD) or registered dietitian nutritionist (RDN), pharmacist, or healthcare provider. No supplement is intended to treat, cure, or prevent disease.

Age-Related Cognitive Decline

Citicoline supplementation improved memory in older adults with age-associated memory impairment compared to a placebo (no treatment) group. However, the study is not generalizable to young adults or people with cognitive diseases like dementia and Alzheimer’s disease (AD).

A review of a collection of studies showed a positive effect of citicoline on cognitive function in people with mild vascular cognitive impairment, vascular dementia, or AD. Because citicoline was used with the standard treatment (acetylcholinesterase inhibitor) for AD, the effect of citicoline alone on AD is unclear.

Cognitive Enhancement

In a study, a citicoline-caffeine-based drink improved attention, mental alertness, and memory. Since citicoline was combined with caffeine, it is unclear what the effect of citicoline alone is on attention and memory.

Based on a study in young, healthy males, citicoline improved motor function and attention after four weeks of supplementation. However, study results might not apply to populations other than young, healthy males.

Eye Surgery Recovery

Using citicoline eye drops three times a day for one month after eye surgery aided the recovery of corneal sensitivity after LASIK (laser-assisted in situ keratomileusis).

Stroke Treatment

A systematic review of studies found citicoline alone benefited acute ischemic stroke (blood clots in the brain). However, citicoline offers limited benefits on top of standard stroke treatment with rtPA or recombinant tissue plasminogen activator (clot-busting drug).

Furthermore, one study in people with a first ischemic stroke showed that after the stroke, people who received citicoline over two years had reduced cognitive impairment.

Neuroprotection

Citicoline has been studied for the following neuroprotective (protecting the nerves and brain) effects:

While citicoline may benefit various cognitive conditions, further research is needed to confirm these results.

Food Sources

Besides supplementation, another way to increase citicoline levels is by consuming cytidine- and choline-rich foods. Citicoline is composed of cytidine and choline. Cytidine is found in meat, especially organ meats.

Foods rich in choline include the following:

• Beef liver, pan-fried, 3 ounces (356 mg per serving)
• Egg, hard-boiled, 1 large egg (147 mg per serving)
• Beef top round, separable lean only, braised, 3 ounces (117 mg per serving)
• Chicken breast, roasted, 3 ounces (72 mg per serving)
• Beef, ground, 93% lean meat, broiled, 3 ounces (72 mg per serving)
• Fish, cod, Atlantic, cooked, dry heat, 3 ounces (71 mg per serving)
• Beans, kidney, canned, one-half cup (45 mg per serving)
• Quinoa, cooked, 1 cup (43 mg per serving)
• Brussels sprouts, boiled, one-half cup (32 mg per serving)
• Broccoli, chopped, boiled, drained, one-half cup (31 mg per serving)
  

Dosage

The usual therapeutic dose for humans used in clinical trials is 500 to 2,000 mg daily.

Listed below are the citicoline dosing for various conditions used in clinical trials.

• Add-on therapy in PD: Usual treatment with levodopa/carbidopa for five weeks plus citicoline 1,000 mg intravenously daily from weeks three to five.

• Add-on therapy in MDD: Citicoline 100 mg by mouth every 12 hours plus Celexa 20 mg per day (for the first week) and 40 mg daily by mouth for the following five weeks.
   
• Add-on therapy in schizophrenia: 1,000 milligrams (mg) by mouth per day for three days, 2,000 mg per day (in two divided doses) on day four for four days, and 2,500 mg per day (in two divided doses) starting week two; used with up to 6 mg of risperidone daily in the study.

• Age-related cognitive decline: Two 250 mg capsules of citicoline (500 mg/day) by mouth with breakfast for 12 weeks.

• Cocaine dependence in bipolar I disorder: 500 mg by mouth per day for one week, then 1,000 mg per day at week two, 1500 mg per day at week four, and 2,000 mg per day at week six, for 12 weeks total.

• Cognitive enhancement: Beverage consisting of 250 mg of citicoline and caffeine (amount unclear).
  For motor function and attention in adolescent males, 250 or 500 mg capsule by mouth per day for 28 days.

• Glaucoma: Citicoline oral solution of 50 mg per milliliter (mL) (mg/mL) used for a daily dose of 10 mL or 500 mg of citicoline by mouth in the morning.

• Head injury: For moderate to severe head injury, 2 g by mouth for 60 days; for severe head injury, 3 g intravenously (IV) for 21 days.

• Stroke treatment: 250 to 2,000 mg from 10 days to six weeks. In the clinical trials, citicoline was given intravenously, orally, or both intravenously and orally;
  for cognitive impairment in people poststroke, 1 gram (g) daily by mouth for two years.

• Methamphetamine dependence: 1 gram (g) of CDP-choline capsule by mouth twice daily for eight weeks.

• Neuroprotection: In neonates (newborns) with HIE, 10 milligrams (mg) per kilogram (kg) per 12 hours (h) intravenously for four weeks plus other supportive measures.
  
  
• Nonproliferative diabetic retinopathy: One drop of citicoline and vitamin B12 eye drops containing citicoline 2%, hyaluronic acid 0.2%, and cyanocobalamin (vitamin B12) 0.05% into one eye three times daily for 36 months.
  
  

Safety

Citicoline is naturally present in the human body and is a nontoxic substance. Citicoline taken by mouth at amounts of up to 1 g per day has been shown to be safe and well-tolerated.

Overall, citicoline is well-tolerated and has no adverse systemic cholinergic side effects (e.g., increased saliva and tear production, urination and defecation, and decreased heart rate).

Avoid citicoline if you're allergic to it or its components (parts). Seek immediate medical attention if you have a severe allergic reaction (itching, hives, shortness of breath).

Side Effects

Although no serious side effects were noted in some studies, mild side effects include the following:

• Increased appetite
• Weight gain
• Increased flatulence (passing gas)
• Headache
• Increased burping

Common side effects include the following:

• Nausea
• Vomiting
• Dizziness
• Stomach upset
• Fatigue
  

Interactions

While there are few studies on drug interactions with citicoline, citicoline theoretically can increase the effect of levodopa by increasing dopamine levels.

Moreover, citicoline with levodopa allowed for a lower dose of levodopa in studies.

Precautions

Many clinical trials exclude people who are pregnant or breastfeeding. Therefore, the safety of citicoline in people who are pregnant or breastfeeding is unknown. 

Although citicoline is well-tolerated, it is essential not to take more than instructed. 

Please consult with your healthcare provider before starting citicoline. 

Dietary supplements are not regulated like prescription medications in the United States. Therefore, some may be safer than others. When choosing a supplement, consider factors such as third-party testing, potential drug interactions, and other safety concerns. Talk to a healthcare provider or a registered dietitian nutritionist (RD or RDN) about supplement quality and safety.

Similar Supplements

Other supplements that have cognitive-enhancing properties include the following:

• Antioxidant polyphenols: Polyphenols, such as resveratrol, improved cognitive function in people with mild cognitive impairment and Alzheimer’s disease in clinical study.

• B vitamins: B vitamins have decreased cognitive decline, and a higher dietary folate intake has been shown to lower dementia risk.

• Medium-chain triglycerides (MCT): Consuming MCT jelly by mouth three times daily for a daily MCT dose of 17.3 g for 30 days improved cognition in people aged between 57 and 87 years with mild to moderate Alzheimer’s disease.

• Omega-3 fatty acids: An analysis of a collection of studies revealed that omega-3 supplementation affects cognitive function in adults of advanced age in a positive way.

• Selenium: Supplementation with selenium has been shown to improve cognitive function in people with mild cognitive impairment and Alzheimer’s disease.
  
  
• Vitamin D: A clinical trial conducted in China found that daily vitamin D supplementation of 800 international units (IU) by mouth daily for 12 months improved cognitive function by reducing oxidative stress in participants aged 65 and older with mild cognitive impairment.
  
  

Similar to citicoline, the supplements above are believed to improve cognitive function. However, whereas citicoline is naturally found in the human body as CDP-choline, the above supplements are not produced by the human body.

Summary

Not only does citicoline protect the brain, but it also has an excellent safety profile. 

Several clinical studies indicate citicoline's therapeutic potential in various neurological conditions, including age-related cognitive decline and stroke treatment and recovery.

Frequently Asked Questions

• How does citicoline work to improve cognitive function?

  Citicoline works to improve cognitive function by increasing brain choline and promoting the production of acetylcholine, a neurotransmitter essential for memory. Additionally, citicoline increases levels of dopamine, norepinephrine, and serotonin.

• How is citicoline administered?

  Citicoline is administered via the following routes: oral (by mouth), intravenous (within a vein), or intramuscular (within a muscle).
  

• What is the difference between citicoline and choline?

  Once citicoline is ingested, it is broken down into two molecules: cytidine and choline.

  After these two molecules cross the blood-brain barrier separately and reach the brain cells, they combine to form CDP-choline (citicoline) again.
  

  Citicoline serves as a source for making phosphatidylcholine, one of the parts of cell membranes.

  Choline, one of the breakdown products of citicoline, serves as one of the building blocks for the production of acetylcholine, a neurotransmitter (chemical messenger) involved in memory and muscle movement.

  Contact us to discuss your requirements of High Quality Phosphatidylserine. Our experienced sales team can help you identify the options that best suit your needs.